» Articles » PMID: 8878456

Interleukin-6 and Granulocyte Colony-stimulating Factor Synergistically Increase Peripheral Blood Progenitor Cells in Myelosuppressive Mice

Overview
Specialty Oncology
Date 1996 Sep 1
PMID 8878456
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported a successful peripheral blood stem cell harvest by co-administration of recombinant human (rh) interleukin-6 (IL-6) and rh granulocyte colony-stimulating factor (G-CSF) in normal mice. In the present study, to evaluate further the utility of this observation for autologous peripheral blood stem cell transplantation, we examined the effects of rhIL-6 and rhG-CSF on peripheral blood granulocyte-macrophage colony-forming units (CFU-GM) in carboplatin (CBDCA)-induced and irradiation-induced myelosuppressive mouse models. After CBDCA administration, blood cell counts decreased to the nadir, and then recovered to a normal level. In this recovery phase, the peripheral CFU-GM level increased to 3.8-fold higher than the pretreatment level. Administration of rhIL-6 (10 microgram/day) alone induced a 40-fold increase in peripheral CFU-GM from the normal level at day 14. In combination with rhG-CSF (0.35 microgram/day), which alone induced a 74-fold increase, rhIL-6 synergistically increased the CFU-GM level by 1200-fold. In irradiated mice, similar results were observed. Administration of rhIL-6 at 3 and 10 microgram/day significantly increased CFU-GM. Interestingly, in combination with rhG-CSF, a lower dose of rhIL-6 (1 microg/day) could induce CFU-GM increase. We also examined CFU-GM distribution in bone marrow, spleen and peripheral blood. Cytokine administration induced not only a change of CFU-GM distribution, but also an increase in total CFU-GM counts per mouse. These results suggest that co-administration of rhIL-6 and rhG-CSF may be useful for autologous peripheral blood stem cell transplantation.

Citing Articles

Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis.

Zhang P, Iwama A, Datta M, Darlington G, Link D, Tenen D J Exp Med. 1998; 188(6):1173-84.

PMID: 9743535 PMC: 2212540. DOI: 10.1084/jem.188.6.1173.

References
1.
Schaafsma M, Fibbe W, Van der Harst D, Duinkerken N, Brand A, Osanto S . Increased numbers of circulating haematopoietic progenitor cells after treatment with high-dose interleukin-2 in cancer patients. Br J Haematol. 1990; 76(2):180-5. DOI: 10.1111/j.1365-2141.1990.tb07869.x. View

2.
Hohaus S, Goldschmidt H, Ehrhardt R, Haas R . Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. Exp Hematol. 1993; 21(4):508-14. View

3.
Elias A, Ayash L, Anderson K, Hunt M, Wheeler C, Schwartz G . Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 1992; 79(11):3036-44. View

4.
Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R . Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood. 1992; 79(5):1193-200. View

5.
Okano A, Suzuki C, Takatsuki F, Akiyama Y, Koike K, Ozawa K . In vitro expansion of the murine pluripotent hemopoietic stem cell population in response to interleukin 3 and interleukin 6. Application to bone marrow transplantation. Transplantation. 1989; 48(3):495-8. DOI: 10.1097/00007890-198909000-00028. View